Monoclonal Antibodies - Information for Providers

Casirivimab/imdevimab, bamlanivimab/etesevimab, and sotromivab were granted emergency use authorization for the treatment of mild to moderate COVID-19. Until the national supply of these monoclonal antibodies (mAbs) is sufficient, the Iowa Department of Public Health and the United States government will help facilitate allocation across Iowa. 

Find a COVID-19 Monoclonal Antibody Provider

HHS mAb Site Locator     NICA mAb Site Locator

Request COVID-19 Monoclonal Antibodies

Casirivimab/imdevimab, bamlanivimab/etesevimab and sotromivab are available at no cost to healthcare providers. Healthcare providers can submit a request to the Iowa Department of Public Health. This request will be added to a list of eligible recipients for monoclonal antibody products for future allocations. Eligibility is not a guarentee for receiving future allocations of monoclonal antibody products.

 Additional information on the distribution process can be found here.

General Resources

Bamlanivimab/Etesevimab (Eli Lilly)

Casirivimab/Imdevimab (Regeneron)

Sotromivab (GSK)


For questions, please contact Combat COVID Monoclonal Antibodies Call Center at 877-332-6585.